Dr. Yara Abdou, MD
Claim this profileUniversity of North Carolina at Chapel Hill
Studies Breast Cancer
Studies PD-L1 Negative
3 reported clinical trials
7 drugs studied
Area of expertise
1Breast Cancer
Stage IV
Stage III
HER2 negative
2PD-L1 Negative
Stage IV
ER negative
PR negative
Affiliated Hospitals
Clinical Trials Yara Abdou, MD is currently running
Sacituzumab Govitecan + Pembrolizumab
for Triple Negative Breast Cancer
This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: * Sacituzumab govitecan (Trodelvy™;IMMU-132) * Pembrolizumab (Keytruda®; MK-3475)
Recruiting1 award Phase 215 criteria
Avelumab Combinations
for Triple Negative Breast Cancer
This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-in of medications that can stimulate the immune system. It is our hope that this induction will improve the response to immunotherapy with avelumab. One treatment, sacituzumab Govitecan, is a monoclonal antibody called sacituzumab linked to a chemotherapy drug called SN-38. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as Tumor-associated calcium signal transducer 2 (TROP2) receptors, and delivers SN-38 to kill them. Another treatment, liposomal doxorubicin, is a form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin, and may enhance factors associated with immune response. The third medication is called binimetinib, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may help activate the immune system. It is not yet known whether giving avelumab in combination with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan will work better in treating patients with triple negative breast cancer.
Recruiting1 award Phase 211 criteria
More about Yara Abdou, MD
Clinical Trial Related4 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Yara Abdou, MD has experience with
- Avelumab
- Sacituzumab Govitecan
- Palbociclib
- Fulvestrant
- Pembrolizumab
- Liposomal Doxorubicin
Breakdown of trials Yara Abdou, MD has run
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Yara Abdou, MD specialize in?
Yara Abdou, MD focuses on Breast Cancer and PD-L1 Negative. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are Stage III.
Is Yara Abdou, MD currently recruiting for clinical trials?
Yes, Yara Abdou, MD is currently recruiting for 2 clinical trials in Chapel Hill North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Yara Abdou, MD has studied deeply?
Yes, Yara Abdou, MD has studied treatments such as Avelumab, Sacituzumab Govitecan, Palbociclib.
What is the best way to schedule an appointment with Yara Abdou, MD?
Apply for one of the trials that Yara Abdou, MD is conducting.
What is the office address of Yara Abdou, MD?
The office of Yara Abdou, MD is located at: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 United States. This is the address for their practice at the University of North Carolina at Chapel Hill.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.